Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Cysic Cysic +23.33%
#4 Solv Protocol xSolvBTC Solv Protocol xSolvBTC +22.84%
#5 Victoria VR Victoria VR +21.15%
#6 Nockchain Nockchain +18.95%
#7 Bedrock Bedrock +17.00%
#8 Versatize Coin Versatize Coin +12.50%
#9 Perle Perle +12.25%
#10 Velvet Velvet +12.00%
Coin of the day
EXOD EXOD
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Peak Bio, Inc. Peak Bio, Inc.

Peak Bio, Inc.

PKBO
Clasificación en acciones #37553
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical... Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.
Precio por acción
$0.07
Última sincronización: 2024-11-12
Capitalización bursátil
$1.62M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Peak Bio, Inc. (PKBO)

Categoría

Healthcare
Ganancias de Peak Bio, Inc. (PKBO)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Peak Bio, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Peak Bio, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE